{
    "elements": [
        {
            "type": "table",
            "sequence_num": 1,
            "data": {
                "num_rows": 15,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "RESEARCH & DEVELOPMENT INITIATION"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "MEHTSOP049"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP)"
                    },
                    {
                        "text": "SOP"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "All staff"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "th11 December 2019"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "th10 December 2022"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "Service Development"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "17"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Research & Development"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Lauren Perkins, R & D Manager"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\uf0fcMEHT \u25a1 BTUH \u25a1 SUH"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Research and Development"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "05/07/2019"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Tracey Camburn R & D Director, Clinical Lead Nurse"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "26/07/2019"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "DRAG Chair's Action"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "11th December 2019"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group"
                    },
                    {
                        "text": "Date: December 2019"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "Intranet & Website"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 2,
            "data": {
                "url": "MEHTSOP049 Initiation 1.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 3,
            "data": {
                "num_rows": 13,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Consulted With:"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Dane Goodere-Bennett"
                    },
                    {
                        "text": "Primary Care Research Facilitator"
                    },
                    {
                        "text": "05/07/2019 05/07/2019"
                    },
                    {
                        "text": "Mandy Lyle"
                    },
                    {
                        "text": "Research Nurse"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "MEHTSOP004 SAEs (Sponsored) MEHTSOP005 Informed Consent MEHTSOP062 TMF MEHTSOP004 Research Staff Training SOP-07 Role of the CI, Pharmacy and R&D MEHTSOP059 Amendments MEHTSOP058 Serious Breaches (Sponsored) MEHTSOP004 Organisation Oversight MEHTSOP004 Research Applications MEHTSOP004 Writing Research Protocols MEHTSOP054 CRF & Data Management (Sponsored) MEHTSOP051 DSURs (Sponsored) MEHTSOP050 Archiving MEHTSOP045 Trial Closure (Sponsored/Hosted) MEHTSOP046 End of Trial Reports MEHTSOP044 Source Data"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 10,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Newly created"
                    },
                    {
                        "text": "11th December 2019"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 6,
            "data": {
                "is_heading": 1,
                "text": "Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Background"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Purpose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Scope"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Applicable to"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Procedure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "References"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "Equality Impact Assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 0,
                "text": "Appendix 1 \u2013 Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 0,
                "text": "Appendix 2 \u2013 Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "BACKGROUND"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "This document sets out the procedures to be followed by all Mid Essex Hospital Services NHS Trust (MEHT) staff who are involved in the recruitment and initiation of investigator sites for research projects sponsored by MEHT."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "It provides guidance on the steps involved in the selection of sites, the assessment and initiation of a site, and who is responsible for obtaining the local approvals necessary for a study to commence, to ensure compliance with the Trust's policies."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "PURPOSE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "The purpose of this SOP is to describe the responsibilities and procedures prior to, during and following the trial initiation visit(s)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 0,
                "prefix": 2.2,
                "text": "Initiation of MEHT Sponsored CTIMPs and participating sites (for multicentre trials) ensures that all the required trial documentation are in place and that the trial procedures are reviewed with the Chief Investigator (CI) / Principal Investigator (PI) and the wider study team in accordance with the trial protocol, trust SOPs, GCP and the applicable regulatory requirements."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 0,
                "prefix": 2.3,
                "text": "Trial/site initiation is integral to the Quality Control (QC) to ensure the quality of every aspect of the clinical trial including the participating sites involved in Trust Sponsored CTIMPs."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 0,
                "prefix": 2.4,
                "text": "In the Clinical Trials Regulations it is a GCP requirement that,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The Investigator and Sponsor shall consider all the relevant guidance with respect to commencing and conducting a clinical trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Before the trial is initiated, foreseeable risks and inconveniences have been weighed against the anticipated benefit for the individual trial subject and society. A trial should be initiated and continued only if the anticipated benefits outweigh the risks"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 0,
                "text": "\u25cf A trial shall be initiated only if the REC and the Licensing Authority (MHRA) comes to the conclusion that the anticipated therapeutic benefit and public health benefits justify the risks and may be continued only if compliance with this requirement is permanently monitored"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 0,
                "prefix": 2.5,
                "text": "The initiation of the trial within the Trust and participating sites (where applicable) ensures;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 29,
            "data": {
                "is_heading": 0,
                "text": "\u25cf All Regulatory and Research Governance approvals are in place prior to commencement of the trial and providing the regulatory green light to commence recruitment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Documented evidence is in place that the site is aware of the Sponsor's procedures outlined within the Trial Protocol and Sponsor's SOPs and their responsibilities in order to ensure the quality of every aspect of the conduct of the study"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Each participating site is aware of their responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 0,
                "text": "\u25cf All other essential documents are in place prior to the study commencing in accordance with the approved protocol and Sponsor SOPs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 0,
                "text": "\u25cf An effective working rapport is established with the study trial team/site and its staff prior to recruitment of trial participants"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 0,
                "text": "\u25cf That all study staff involved in the trial have documented GCP training which is current and up to date within the past 2-3 years as per gSOP-06"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The Delegation of duties for the study has been discussed and is adequately completed and authorised by the CI/PI for all applicable site staff before any trial related activity has occurred"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The clinical trial pharmacist(s) is provided with the notification to proceed with ordering the IMP and that the procedures for receipt, dispensing, accountability, and other related documents, as specified in the applicable pharmacy SOP, are present"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "SCOPE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "An Initiation visit/meeting should take place for all participating sites prior to Sponsor authorisation being issued for the site to commence recruitment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 0,
                "prefix": 3.2,
                "text": "The study/site initiation may take one or more of the following forms and should be recommended by and documented within the study specific monitoring plan;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Single centre CTIMPs: A study team pre-activation initiation visit conducted by the CI/delegated individual (DI) prior to issue of the final R&D confirmation letter"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Multi-centre CTIMPs: An on site initiation visit to the participating site conducted by an adequately trained study team member from the Sponsor organisation. Where required the CI/DI may also attend the site initiation to provide additional support during the visit. All key study team members from the participating site should attend the initiation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Conference call"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Telephone call with site in circumstances where the options listed above are not feasible with the study site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "APPLICABLE TO"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 1,
                "prefix": 4.1,
                "text": "Any relevant Trust employee (including those with an honorary research contract or letter of access) involved with CTIMP clinical research sponsored by MEHT including, Unit Heads, Chief Investigators (CI), Principal Investigators (PI), Consultants, Co-investigators, Research Fellows, Clinical Trial Pharmacists, Research Managers, Statisticians, Research Nurses, Allied Health Professionals , Trial Coordinators & Data Managers."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "RESPONSIBILITIES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 1,
                "prefix": 5.1,
                "text": "The Sponsor should ensure;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The quality control of all Trust sponsored CTIMPs. A Site initiation visit should be completed to ensure the quality of the setup of the trial and compliance with the currently approved protocol/amendments(s), GCP, Trust policies, SOPs and the applicable UK clinical trial regulations"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The CI/DI is appropriately qualified and trained in order to have the scientific and/or clinical knowledge to initiate the trial adequately"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 1,
                "prefix": 5.2,
                "text": "The CI/DI should ensure that;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The trial does not commence without the completion of an initiation visit (for all single and multi-centre CTIMPS)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The site PI is present during the initiation visit/conference/telephone call for all participating sites in multi-centre CTIMPs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 1,
                "text": "\u25cf Where a participating site has been initiated, oversight of this process has been demonstrated by completion of the initiation visit checklist, prior to the issue of the Regulatory green light for the site to commence recruitment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 0,
                "prefix": 5.3,
                "text": "The Clinical Trials Pharmacist/DI should ensure that;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The required set up procedures are completed as described in the applicable pharmacy SOPs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 0,
                "text": "\u25cf For multi-centre trials a pharmacy pack has been completed and included as part of the site initiation guidance pack."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Where required they are available to attend initiation conferences/telephone initiations where specific input/training is required for the site pharmacy staff (As recommended by the study monitoring plan)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "PROCEDURES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "Prior to the initiation visit/meeting the CI/DI should ensure;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 1,
                "text": "6.1.1 Single centre trials"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 1,
                "text": "The collection and verification of all approvals and essential documentation according to the initiation visit checklist. For Single Centre CTIMPs the CI/DI should ensure that all the applicable essential documentation is maintained within the main study TMF and the Sponsor R&D file."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 1,
                "text": "6.1.2 Multi-centre Trials"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 63,
            "data": {
                "is_heading": 0,
                "text": "6.1.3 The site feasibility questionnaire has been completed and received from the participating site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 0,
                "text": "6.1.4 Participating sites should be in receipt of the relevant study specific documentation in the form of the study initiation guidance pack for completion of the Investigator Site File."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 0,
                "text": "6.1.5 The following documents are requested from the site and present in the TMF (site level) as a minimum:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 0,
                "text": "- Completed site feasibility questionnaire"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 67,
            "data": {
                "is_heading": 0,
                "text": "- Site R&D confirmation (including subsequent R&D amendments)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 0,
                "text": "- Fully signed Clinical Trial site agreement"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 0,
                "text": "- Signed PI protocol authorisation signature page"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 0,
                "text": "- Local institution headed information to be provided to research participants (e.g. Informed Consent Forms, Participant Information Sheets, questionnaires)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 71,
            "data": {
                "is_heading": 0,
                "text": "- Completed Delegation of Responsibilities log"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 0,
                "text": "- Completed site source document location identification sheet (PI signature)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 73,
            "data": {
                "is_heading": 0,
                "text": "- PI CV (copy)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 0,
                "text": "- PI GCP training certificate (copy)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 0,
                "text": "- Completed copy of the source document location identification sheet"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 0,
                "text": "- Copy of trial site laboratory accreditations/reference ranges"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 0,
                "text": "- Copies of signed consent forms"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 0,
                "text": "6.1.6 The CI/PI and the other relevant trial/site staff have had up to date training in the relevant areas. In addition to GCP training completion the CI/DI should ensure that the trial team have completed the required mandatory training as per trust SOPs and policies."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 79,
            "data": {
                "is_heading": 0,
                "text": "6.1.7 Where a conference/telephone call is planned to function as the initiation process that all the relevant participating site staff receive the study specific initiation training presentation slides and sign the initiation training log."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 0,
                "text": "6.1.8 Ensure that the CI/PI and relevant trial staff including the trial pharmacy staff are made aware of the initiation visit, format, objective and expectations and are able to attend. It is mandatory that the CI and PI are present during the visit. A site initiation invitation email/letter should be issued to the site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 1,
                "prefix": 6.2,
                "text": "During the Initiation visit"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 1,
                "text": "6.2.1 Single centre trials or Multi-Centre"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 0,
                "text": "6.2.2 Provide the initiation presentation training as required, to include training in the sponsor SOPs and protocol specific requirements for multi-centre studies where a conference/telephone call is the specified method for initiation, the opportunity for the site team to answer questions regarding the initiation handouts and other trial specific information should be given. Any issue highlighted at initiation which are not resolved at that time point should be followed up after the visit and specified on the initiation visit checklist."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 84,
            "data": {
                "is_heading": 0,
                "text": "6.2.3 Ensure that the CI/PI and relevant trial staff sign the initiation visit/meeting attendance log."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 0,
                "text": "6.2.4 Verify that the CI has signed the delegation of responsibilities log. Where possible the CI/DI should verify that the CI has authorised the delegation of duties for the relevant trial staff including the pharmacy study staff. This should be an ongoing process throughout the course of the study."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 0,
                "text": "6.2.5 Ensure that the CI/PI has defined what will be considered as source data for the trial and that this has been adequately authorised and verified during the visit."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 0,
                "text": "6.2.6 Ensure that the CI/PI is aware of their obligation to provide direct access to source documents for each trial participant and how this will be achieved."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 0,
                "text": "6.2.7 Ensure that the CI/PI and relevant trial/site staff are aware of the sponsor's requirements for recording and reporting adverse events and potential serious breaches of GCP/trial protocol or implementation of urgent safety measures (see gSOP-09)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 0,
                "text": "6.2.8 Verify that the correct version(s) of the safety profiles for the IMP(s) are available and retained within the TMF (Investigator's Brochure and/or summary of product characteristics (see gSOP-05)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 0,
                "text": "6.2.9 Review and verify that all the IMP(s) procedures including, but not limited to receipt, storage, dispensing, accountability, return and destruction."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 0,
                "text": "6.2.10 Review and verify the storage conditions and methods for monitoring storage of the IMP(s) even if the IMP has not arrived on site. In addition and where applicable verify the storage conditions and custody of sample management for trial specific samples. Where the IMP(s) have not arrived on site the delegated individual should ensure that a separate visit to pharmacy is scheduled upon receipt of the IMP. For multi-centre CTIMPs the delegated study team member conducting the initiation visit should ensure that the site are in receipt of the pharmacy pack and provide the opportunity for the site to ask questions relevant to the management of the IMP(s) before the site is activated."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 0,
                "text": "6.2.11 Verify that the CI/PI has all of the appropriately trained staff, facilities and equipment to perform the trial according to the trial protocol and all the protocol specific requirements (including the management and oversight of any trial related samples)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 0,
                "text": "6.2.12 Ensure that the C/PI is aware of the extent and method of the monitoring to be performed for the study as detailed in study specific monitoring plan."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 0,
                "text": "6.2.13 Ensure that participating sites are aware of their responsibility to inform the CI/DI if they are notified of any upcoming (regulatory or internal) inspections or audits."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 0,
                "text": "6.2.14 Ensure that the CI is aware of all their contractual obligations and reporting obligations to external parties (where required)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 0,
                "text": "6.2.15 Ensure that the CI/PI is aware of their responsibility to ensure adequate cover during absences and of their obligation to have ongoing oversight of the trial."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 0,
                "text": "6.2.16 As part of the initiation process for multi-centre CTIMPs where a conference/telephone call initiation is conducted the study team should ensure that the Initiation visit checklist is completed prior to activation of the site. This may be done in real time during the meeting or following the meeting. An Initiation visit checklist should be completed for all the participating sites and retained within the TMF (site level) within the coordinating office. The completed site initiation visit checklist should be forwarded to the R&D department electronically for verification prior to final sign off."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 1,
                "prefix": 6.3,
                "text": "Following the initiation visit"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 1,
                "text": "6.3.1 Single centre CTIMPs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 0,
                "text": "6.3.2 Authorisation of the Initiation visit checklist"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 0,
                "text": "6.3.3 Resolution of critical issues prior to the issue of the final confirmation letter"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 0,
                "text": "6.3.4 Once outstanding issues resolved issue the R&D confirmation letter to the study team"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 0,
                "text": "6.3.5 Information sent by the CI to pharmacy and any other relevant support departments including as a minimum the R&D confirmation letter, regulatory approval letters, protocol, protocol authorisation signature page, signed agreements (copies)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 0,
                "text": "6.3.6 Upload approved protocol onto the hospital intranet document repository"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 105,
            "data": {
                "is_heading": 0,
                "text": "6.3.7 Ensure  the  trial  is  active  on  the  trust  R&D  database  with  applicable  essential documentation uploaded as required"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 106,
            "data": {
                "is_heading": 1,
                "text": "6.3.8 Multi centre CTIMPs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 107,
            "data": {
                "is_heading": 0,
                "text": "6.3.9 Authorisation of the Initiation Visit Checklist (CI/DI)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 0,
                "text": "6.3.10 Resolution of critical issues prior to issue of site \u2018green light Sponsor authorisation to commence recruitment email'"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 109,
            "data": {
                "is_heading": 0,
                "text": "6.3.11 Ensure site specific essential documents and completed attendance logs/training records are filed in the site level TMF at coordinating centre."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 110,
            "data": {
                "is_heading": 0,
                "text": "6.3.12 Pharmacy to send \u2018green light Sponsor authorisation to commence recruitment' as an email/letter to the site coordinating team and site trial pharmacy staff."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "REFERENCES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 0,
                "text": "ICH GCP"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 0,
                "text": "UK policy framework for health and social care research"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 114,
            "data": {
                "is_heading": 0,
                "text": "The Medicines for Human Use (Clinical Trials) (2004) regulations"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "EQUALITY IMPACT ASSESSMENT"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 116,
            "data": {
                "is_heading": 0,
                "prefix": 9.1,
                "text": "Mid Essex Hospital Services NHS Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals. (Refer to Appendix 3)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 117,
            "data": {
                "is_heading": 1,
                "text": "Appendix 1: Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 118,
            "data": {
                "is_heading": 1,
                "text": "Adverse Event (AE) -  Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 119,
            "data": {
                "is_heading": 1,
                "text": "Case Report Form (CRF) - A printed, optical, or electronic document designed to record all of the protocol required information to be reported to the sponsor on each trial subject."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 120,
            "data": {
                "is_heading": 1,
                "text": "Chief Investigator (CI) -  The person who takes overall responsibility for the design, conduct and reporting of a study if it is at one site; or if the study involves researchers at more than one site, the person who takes primary responsibility for the design conduct and reporting of the study whether or not that person is an Investigator at any particular site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 121,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial - Any investigation in human subjects, other than a non-interventional trial intended to discover or verify the clinical, pharmacological or other pharmacodynamic effects of one or more medicinal product or to identify any adverse reactions to one or more such products and to study absorption, distribution metabolism and excretion in one of more such products with the object of ascertaining the safety or efficacy of those products."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 122,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial of an Investigational Medicinal Product (CTIMP) - This is defined as any Clinical Research Study which intends to generate new information about the safety or efficacy of a Medicinal Product."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 123,
            "data": {
                "is_heading": 1,
                "text": "Delegated Individual (DI) - An individual delegated by the PI to carry out their task(s)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 124,
            "data": {
                "is_heading": 1,
                "text": "Good Clinical Practice (GCP) - The principles of Good Clinical Practice in Clinical Trials as set down in Articles 2-5 of the GCP Directive and implemented in the UK by Schedule 1 of the Medicines for Human Use (Clinical Trials) Regulations 2004 (S.I.2004/1031) as amended by S.I. 2006/1928."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 125,
            "data": {
                "is_heading": 0,
                "text": "Good Clinical Practice is a set of internationally recognised ethical and scientific quality requirements which must be observed for designing, conducting, recording and reporting clinical trials that involve the participation of human subjects."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 126,
            "data": {
                "is_heading": 1,
                "text": "Honorary Research Contract (HRC) - HRCs are required for researchers who are not employees of the NHS and whose activities could have a foreseeable and direct impact on patient care."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 127,
            "data": {
                "is_heading": 1,
                "text": "International Conference on Harmonisation (ICH) -  International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use is a joint initiative involving both regulators and research-based industry focusing on the technical requirements for medicinal products containing new drugs."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 128,
            "data": {
                "is_heading": 1,
                "text": "Investigational Medicinal Products (IMP) -  A pharmaceutical form of an active substance or placebo being tested, or used as a reference in a clinical trial. This includes a medicinal product which has a marketing authorisation but is, for the purposes of the trial -"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 129,
            "data": {
                "is_heading": 0,
                "text": "\u25cf used or assembled (formulated or packaged) in a way different from the form of the product authorised under the authorisation,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 130,
            "data": {
                "is_heading": 0,
                "text": "\u25cf used for an indication not included in the summary of product characteristics under the authorisation for that product, or"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 131,
            "data": {
                "is_heading": 0,
                "text": "\u25cf used to gain further information about the form of that product as authorised under the authorisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 132,
            "data": {
                "is_heading": 1,
                "text": "Investigator Site File (ISF) - The file(s) held at each site taking part in the trial which hold the essential trial document set necessary for local approval and trial conduct at site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 133,
            "data": {
                "is_heading": 1,
                "text": "Letter of Access - Letters of access enable NHS employees or staff with an honorary clinical contract (e.g. clinical academics) with one NHS organisation to conduct research in another NHS organisation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 134,
            "data": {
                "is_heading": 1,
                "text": "Mandatory - Training which must be completed by all employees and any other staff involved in clinical trials and is therefore compulsory."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 135,
            "data": {
                "is_heading": 1,
                "text": "Monitoring - A quality control (QC) activity which involves a system of ongoing real time checks to detect discrepancies and faults in order to correct them, and prevent the failure from recurring so that the specified output is produced consistently, in this context compliance with the UK Regulations, Sponsor SOPs, approved protocol and GCP."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 136,
            "data": {
                "is_heading": 1,
                "text": "Monitoring Plan - The agreed process for monitoring a CTIMP sponsored by MEHT as specified in the study monitoring plan determined by the risk based monitoring strategy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 137,
            "data": {
                "is_heading": 1,
                "text": "Participant Information Sheet (PIS) -  A document that explains all relevant study information to assist the trial participant in understanding the expectations and requirements of participation in a clinical trial."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 138,
            "data": {
                "is_heading": 1,
                "text": "Pharmacovigilance - The regulations outline procedures for the recording and reporting of safety events (adverse events or suspected unexpected serious adverse reactions) arising from clinical trials."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 139,
            "data": {
                "is_heading": 1,
                "text": "Pharmacy Pack - The Pharmacy Pack must cover the following:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 140,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Contact details of sponsor"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 141,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Trial synopsis, with reference to which version of the protocol pack has been prepared with."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 142,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Study medication:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 143,
            "data": {
                "is_heading": 0,
                "text": "\u25cb Formulation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 144,
            "data": {
                "is_heading": 0,
                "text": "\u25cb Storage"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 145,
            "data": {
                "is_heading": 0,
                "text": "\u25cb Labelling/Labels"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 146,
            "data": {
                "is_heading": 0,
                "text": "\u25cb Reconstitution / Dilution or (Aseptic) preparation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 147,
            "data": {
                "is_heading": 0,
                "text": "\u25cb Stability"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 148,
            "data": {
                "is_heading": 0,
                "text": "\u25cb Administration"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 149,
            "data": {
                "is_heading": 0,
                "text": "\u25cb Ordering & receipt of first and subsequent supplies"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 150,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Randomisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 151,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Prescribing"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 152,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Dispensing"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 153,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Accountability forms"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 154,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Patient returns"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 155,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Destruction and Hazards"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 156,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Forms/Templates"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 157,
            "data": {
                "is_heading": 1,
                "text": "A Pharmacy Trial File -  A collection of files that contain all the pharmacy relevant documents pertaining to a specific clinical trial."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 158,
            "data": {
                "is_heading": 1,
                "text": "Principal Investigator (PI) - The leader responsible for a team of individuals conducting a study at a (participating) site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 159,
            "data": {
                "is_heading": 1,
                "text": "Quality Control (QC) - The operational techniques and activities undertaken within the quality assurance system to verify that the requirements for quality of the trial-related activities have been fulfilled."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 160,
            "data": {
                "is_heading": 1,
                "text": "Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR) - Any untoward medical occurrence or effect that at any dose results in:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 161,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Death"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 162,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Is life-threatening*"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 163,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Requires hospitalisation or prolongation of existing hospitalisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 164,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Results in persistent or significant disability or incapacity"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 165,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Is a congenital anomaly or birth defect"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 166,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Is an important medical event"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 167,
            "data": {
                "is_heading": 0,
                "text": "* \u201clife-threatening\u201d refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 168,
            "data": {
                "is_heading": 1,
                "text": "Site Feasibility Form - The form sent to each site to collect the site contact details e.g. the CI/PI, Trials Pharmacist, Research Nurse or Trial Co-ordinator and allow assessment of site and their facilities versus requirements for a given trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 169,
            "data": {
                "is_heading": 1,
                "text": "Site File - Site Files are held by the Principal Investigator at sites and contain copies of the essential documents, local approvals, signed consent forms and completed data forms."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 170,
            "data": {
                "is_heading": 1,
                "text": "Site Initiation Guidance Pack - This pack is sent both electronically and a hard copy placed in the ISF which contains the following logs tailored to each trial to allow sponsor and site oversight of trial conduct;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 171,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Site Registration Form"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 172,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Coordinating Centre Contact Sheet"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 173,
            "data": {
                "is_heading": 0,
                "text": "\u25cf MEHT TMF Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 174,
            "data": {
                "is_heading": 0,
                "text": "\u25cf CI/PI Protocol Authorisation Signature Sheet"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 175,
            "data": {
                "is_heading": 0,
                "text": "\u25cf MEHT site specific delegation log"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 176,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Subject Screening Log"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 177,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Subject Enrolment, Withdrawal and Study Completion Log"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 178,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Study/Site eSAE log study & specific template & guidance email"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 179,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Subject Master Identification code list"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 180,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Substantial/ Non substantial amendment log"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 181,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Trial Monitoring visit log"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 182,
            "data": {
                "is_heading": 0,
                "text": "\u25cf UK Clinical Trial Regulations Site self-completion compliance checklist & guidance (to include summary monitoring plan requirements and responsibilities for participating sites)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 183,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Study SAE report form, Guidance documents & applicable contacts and PV guidance training presentation slides for MEHT Sponsored CTIMPs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 184,
            "data": {
                "is_heading": 0,
                "text": "\u25cf MEHT potential GCP breach report forms/ Urgent Safety Report Forms and applicable guidance & contacts)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 185,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Pharmacy pack for Multi centre Trials (To include study specific guidance)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 186,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Initiation Presentation slide handouts for staff training (to include protocol specific and Sponsor SOP requirements)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 187,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Study/site initiation attendance log"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 188,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Staff protocol training completion log/ Initiation handout review checklist (participating sites)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 189,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Source Document Location Identification Checklist"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 190,
            "data": {
                "is_heading": 1,
                "text": "Source Document Location Identification Checklist - A quality control document which is reviewed and validated by the CI/PI to ensure consistent management of the location of source data for protocol specific assessment results and diagnostic and or translational research conducted as part of the trial. The document is designed to improve the quality of the management and oversight procedures of source data by the Sponsor."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 191,
            "data": {
                "is_heading": 1,
                "text": "Suspected Unexpected Serious Adverse Reaction (SUSAR) - All suspected adverse reactions related to an investigational medicinal product (IMP) that is both unexpected and serious."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 192,
            "data": {
                "is_heading": 1,
                "text": "The Medicines & Healthcare products Regulatory Agency (MHRA) - The government agency which is responsible for ensuring that medicines and medical devices work, and are acceptably safe."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 193,
            "data": {
                "is_heading": 0,
                "text": "The MHRA can also be defined as:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 194,
            "data": {
                "is_heading": 0,
                "text": "MHRA (Medicines) is the competent authority for the UK in relation to the EU Directive and the Clinical Trials Regulations. MHRA (Devices) is the competent authority for the UK in relation to the Medical Devices Regulations 2002."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 195,
            "data": {
                "is_heading": 1,
                "prefix": 2004.0,
                "text": "The Regulations - Medicines for Human Use (Clinical Trial) Regulations 2004 transposed the EU Clinical Trials Directive into UK legislation, as Statutory Instrument 2004 no 1031. This became effective on the 1st May  An amendment to implement Directive 2005/28/EC was made to the Regulations as Statutory Instrument 2006 no 1928."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 196,
            "data": {
                "is_heading": 1,
                "text": "Trial Initiation Presentation/ Handouts - This is the presentation that will be presented to the CI/PI and their research team at the site and will cover the following topics as a minimum. Topics covered should be completed in the initiation visit checklist."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 197,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Responsibilities of Investigator/Site"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 198,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Delegation of Responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 199,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Sponsor's forms and Logs for trial conduct"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 200,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Sponsors SOPs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 201,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Informed consent and Recruitment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 202,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Trial IMP- storage, ordering supplies, preparation, labelling, dispensing, return/disposal of IMP(s)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 203,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Imaging or other specialist requirements/ procedures"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 204,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Screening procedures"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 205,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Randomisation procedure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 206,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Management of protocol/ treatment deviations"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 207,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Monitoring procedures"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 208,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Data management (CRF completion and expected follow up timeframes)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 209,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Biological Sample handling (if applicable)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 210,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Pharmacovigilance & Urgent Safety Measures"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 211,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Amendments"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 212,
            "data": {
                "is_heading": 0,
                "text": "\u25cf End of Trial and Archiving"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 213,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Ongoing staff Training"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 214,
            "data": {
                "is_heading": 0,
                "text": "\u25cf UK Regulations and CTIMP legislations"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 215,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Sponsor Contact Details"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 216,
            "data": {
                "is_heading": 1,
                "prefix": 2004.0,
                "text": "The UK Clinical Trials Regulations -  Medicines for Human Use (Clinical Trial) Regulations  transposed the EU Clinical Trials Directive into UK legislation, as Statutory Instrument  no  This became effective on the 1st May  An amendment to implement Directive 2005/28/EC was made to the Regulations as Statutory Instrument 2006 no 1928 (and as amended from time to time)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 217,
            "data": {
                "is_heading": 1,
                "text": "Trial Master File (TMF) - The Trial Master File (TMF) will be held at the principal site by the sponsor, Chief Investigator or at the co-ordinating Centre. The TMF should contain all essential documents defined as documents which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. A Trial Master File should be set up at the beginning of a trial and maintained up-to-date throughout the trial until trial conclusion."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 218,
            "data": {
                "is_heading": 0,
                "text": "For trials currently running, it is recommended that Section 8 of the ICH-GCP Guideline is followed as guidance in order to meet statutory requirements. However, some of the documents listed may not be available or applicable in many non-commercial trials. The appropriate documentation will vary according to the trial and sponsor requirements."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 219,
            "data": {
                "is_heading": 1,
                "text": "Trial Site - The location(s) where trial-related activities are actually conducted as per the REC and MHRA submissions."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 220,
            "data": {
                "is_heading": 1,
                "text": "Unexpected Adverse Reaction - An adverse reaction, the nature, or severity of which is not consistent with the applicable product information (e.g. investigator's brochure (IB) for an unapproved investigational product or summary of product characteristics (SmPC) for an authorised product)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 221,
            "data": {
                "is_heading": 1,
                "text": "Unexpected SAE/SAR - An adverse event that meets the definition of serious and is not listed in the protocol, IB, SmPC or the most recent informed consent document for the study (list of unexpected SAE will be trial specific)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 222,
            "data": {
                "is_heading": 0,
                "text": "Research & Development Initiation / MEHTSOP049/1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 223,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 224,
            "data": {
                "is_heading": 1,
                "text": "Appendix 2: Preliminary Equality Analysis"
            }
        },
        {
            "type": "image",
            "sequence_num": 225,
            "data": {
                "url": "MEHTSOP049 Initiation 1.0.002.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 226,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Research & Development Initiation / MEHTSOP049"
            }
        },
        {
            "type": "table",
            "sequence_num": 227,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "A change in a service to patients"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to an existing policy"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to the way staff work"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A new policy"
                    },
                    {
                        "text": "X"
                    },
                    {
                        "text": "Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "New SOP"
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "Review"
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and clinicians"
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change? b) If so, with whom?"
                    },
                    {
                        "text": "Refer to pages 1 and 2"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 228,
            "data": {
                "is_heading": 1,
                "text": "Preliminary analysis completed by:"
            }
        },
        {
            "type": "table",
            "sequence_num": 229,
            "data": {
                "num_rows": 1,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Research & Development Manager"
                    },
                    {
                        "text": "Date"
                    },
                    {
                        "text": "July 2019"
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 230,
            "data": {
                "url": "MEHTSOP049 Initiation 1.0.001.png"
            }
        }
    ]
}